Alkashaf Ahmed, Smith-Cortinez Natalia, Fenton Georgina E, Bok Sebastian Thomas, Stokroos Robert J, Stegeman Inge, Straatman Louise V
Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
BMJ Open. 2025 May 30;15(5):e103296. doi: 10.1136/bmjopen-2025-103296.
To assess whether treatment with drugs that activate the Wnt pathway leads to an increased risk of cancer.
Systematic review reported using Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) reporting guidelines.
PubMed, Embase and the Cochrane Library were searched through 1 November 2024.
All primary research articles reporting clinical studies, including observational and experimental studies, were included in this review. All studies were eligible for inclusion if they included the exposure of interest, that is, compounds which have been described to activate the Wnt pathway, and the outcome of interest, that is, cancer prevalence. No language restrictions were performed.
This study was reported according to the PRISMA reporting guidelines. The search string, objectives, and study protocol methods were defined before the study was initiated.
A total of 48 studies investigating drugs that activate the Wnt pathway (valproic acid, lithium, cimetidine, olanzapine, clozapine, haloperidol) were included in this systematic review. The results from this systematic review show that, at least for the included compounds in the currently used systemic dosage, cancer prevalence does not significantly increase.
The current study found that the use of drugs that activate the Wnt pathway was not associated with an increased risk of cancer. As a promising agent in the regenerative therapy field, further research into Wnt activation as a treatment option should be explored.
CRD42021286193.
评估使用激活Wnt信号通路的药物治疗是否会增加患癌风险。
采用系统评价与Meta分析的规范报告条目（PRISMA）报告指南进行系统评价。
检索了截至2024年11月1日的PubMed、Embase和Cochrane图书馆。
本评价纳入所有报告临床研究的原发性研究文章，包括观察性和实验性研究。如果研究包括感兴趣的暴露因素，即已被描述为激活Wnt信号通路的化合物，以及感兴趣的结局，即癌症患病率，则所有研究均符合纳入标准。没有语言限制。
本研究按照PRISMA报告指南进行报告。在研究开始前确定检索词、目标和研究方案方法。
本系统评价共纳入48项研究，这些研究调查了激活Wnt信号通路的药物（丙戊酸、锂、西咪替丁、奥氮平、氯氮平、氟哌啶醇）。该系统评价的结果表明，至少就目前使用的全身剂量中的纳入化合物而言，癌症患病率没有显著增加。
本研究发现，使用激活Wnt信号通路的药物与患癌风险增加无关。作为再生治疗领域一种有前景的药物，应进一步探索将Wnt激活作为一种治疗选择进行研究。
PROSPERO注册号：CRD42021286193。
